Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Zoledronic acid
Indication
Corticosteroid induced osteoporosis, Increase bone mass in men with osteoporosis, Osteoporosis in postmenopausal women, Paget's disease of bone, Prophylaxis of postmenopausal osteoporosis.
Instruction
Adult: 5 mg as a single infusion over 15 min.
Drug interaction
Increased exposure of concomitant drugs eliminated by renal excretion (e.g. digoxin). Increased risk of hypocalcaemia w/ loop diuretics. Lowered serum Ca concentrations for prolonged periods w/ aminoglycosides. Increased risk of renal dysfunction w/ nephrotoxic agents.
NOVARTIS PHARMA STEIN AG
Contents
Zoledronic acid
Indication
Corticosteroid induced osteoporosis, Increase bone mass in men with osteoporosis, Osteoporosis in postmenopausal women, Paget's disease of bone, Prophylaxis of postmenopausal osteoporosis.
Instruction
Adult: 5 mg as a single infusion over 15 min.
Drug interaction
Increased exposure of concomitant drugs eliminated by renal excretion (e.g. digoxin). Increased risk of hypocalcaemia w/ loop diuretics. Lowered serum Ca concentrations for prolonged periods w/ aminoglycosides. Increased risk of renal dysfunction w/ nephrotoxic agents.
Inquiry - Aclasta Solution for Infusion 5mg/100ml